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Background: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after trau-
matic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot
study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue.
Methods: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study
in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (question-
naires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to
assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomo-
tor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients
were treated with placebo. After a 6-week treatment period, all examinations were repeated.
Results: EDS improved significantly in patients with TBI who were treated with modafinil, com-
pared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakeful-
ness test improved only in the modafinil group. Modafinil, however, had no impact on
posttraumatic fatigue. Clinically relevant side effects were not observed.
Conclusion: This study indicates that modafinil is effective and well tolerated in the treatment of
posttraumatic EDS but not of fatigue.
Classification of evidence: This study provides Class I evidence that modafinil (100–200 mg daily)
improves posttraumatic EDS compared with placebo. This study provides Class I evidence that
modafinil (100–200 mg daily) does not improve posttraumatic fatigue compared with placebo.
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GLOSSARY
EDS  excessive daytime sleepiness; ESS  Epworth Sleepiness Scale; FSS  Fatigue Severity Scale; GCS  Glasgow
Coma Scale; MWTmaintenance of wakefulness test; TBI traumatic brain injury.
Traumatic brain injury (TBI) occurs in about 1.4 million people in the United States each year,
corresponding to an incidence of 460 per 100,000 per year.1 Another study estimated that 3.17
million US citizens (more than 1% of the total US population) have long-term neurologic
disability that resulted from TBI.2 Thus, TBI causes the largest number of disability-adjusted
life-years lost to death and to varying degrees of disability, including posttraumatic sleep-wake
disturbances.3
Excessive daytime sleepiness (EDS) and fatigue are frequent symptoms after TBI. In our
prospective study on posttraumatic sleep-wake disturbances, we studied 65 consecutive pa-
tients by means of questionnaires and sleep laboratory examinations 6 months after trauma.4
We found EDS in 38% and fatigue in 17% of our patients. Our findings are in line with other
reports on posttraumatic sleep-wake disturbances.5-7 The etiology of posttraumatic EDS is not
known. Recently, we found a partial loss of wake-promoting hypothalamic hypocretin (orexin)
neurons after fatal TBI.8 EDS and fatigue significantly impair quality of life and daytime
functioning, including professional performances and social activities.4 Despite their high inci-
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dences, posttraumatic EDS and fatigue are
still underestimated, and there is no treatment
for affected patients.
Thus, with this pilot study, we aimed at
studying the effect of daily modafinil on post-
traumatic EDS and fatigue. Modafinil (2-
[(diphenylmethyl) sulfinyl] acetamide) has
wake-promoting properties and is approved
by the US Food and Drug Administration for
the treatment of EDS in patients with narco-
lepsy, obstructive sleep apnea syndrome, and
shift work sleep disorder.
METHODS This prospective study was conducted at the De-
partment of Neurology of the University Hospital of Zurich,
Switzerland, between January 2007 and June 2009.
Subjects. In this prospective, double-blind, randomized,
placebo-controlled pilot study, we included 20 consecutive pa-
tients from our first study on posttraumatic sleep-wake distur-
bances.4 All patients were admitted for closed mild to severe TBI
to our surgical intensive care unit, where they were recruited for
this study. TBI severity was quantified with the initial Glasgow
Coma Scale (GCS) examination, which was performed immedi-
ately after trauma (mild TBI: GCS 13–15, moderate TBI: GCS
9–12, severe TBI: GCS 3–8). Admission to the surgical inten-
sive care unit was for mild to severe TBI. The mandatory inclu-
sion criterion was the presence of fatigue or EDS or both since
TBI. Patients with neurologic, psychiatric, or other disorders
and medication that might cause sleep-wake disturbances were
not included. Furthermore, we excluded patients who revealed
significant sleep-wake disturbances other than posttraumatic vig-
ilance impairment at baseline examinations. Patients with
chronic sleep deprivation were also excluded. The latter was di-
agnosed in patients with EDS who slept 2 hours more on
weekends or during holidays than during weekdays. All exclu-
sions were made before randomization.
Fatigue was assessed with the Fatigue Severity Scale (FSS),
and EDS was assessed with the Epworth Sleepiness Scale (ESS).
Both scales have been validated in German.9,10 Fatigue is diag-
nosed in patients with FSS values above 4.0, and EDS is diag-
nosed in those with ESS scores 10. Before randomization,
written informed consent was obtained from all patients.
Baseline examinations. At baseline, patients were adminis-
tered the Beck Depression and Anxiety Inventory, a standard
questionnaire to assess depression and anxiety symptoms.11 To
rule out chronic sleep deprivation, patients were examined by 2
weeks of actigraphy studies. Actigraphy is a noninvasive method
to monitor activity/rest cycles over a defined period of time.
Sleep and physical activity levels were recorded by wrist actigra-
phy. The actimeter includes a light sensor and is worn on the
nondominant wrist (Actiwatch, CamNtech Ltd., Cambridge,
UK).12 With this software, the determination of time asleep
and time awake relies on an algorithm using the activity data
recorded by the Actiwatch in a series of linked calculations.
During actigraphy recordings, all patients simultaneously
filled in sleep logs.
Immediately after actigraphy, conventional nocturnal poly-
somnography was recorded from 11 PM to 7 AM. We used a
16-channel recording system (Embla A10, Embla, Broomfield,
CO). Sleep-stage scoring was performed visually by the first au-
thors according to standard criteria.13 Patients with significant
sleep-wake disturbances, such as obstructive sleep apnea, de-
tected during polysomnographic recordings were excluded from
the study. The day after polysomnography, all patients were ex-
amined by a maintenance of wakefulness test (MWT).14 This test
measures the ability to stay awake for 40 minutes while sitting
quietly in a dark room and is performed every 2 hours, in total 4
times a day. Mean sleep latency in the MWT was defined as the
time from lights off to the first epoch of any sleep stage. At the
same day, before every MWT test, we examined the patients’
vigilance with the psychomotor vigilance test. This test measures
reaction times of patients to the sudden appearance of a time-
keeper on a black computer screen.15 The test lasts 10 minutes
and assesses the number of lapses, defined as times the subject
does not respond to the signal in time, and calculates reaction
times. Intake of caffeine and medication with known effects on
vigilance and sleepiness were not allowed during days and nights
with sleep recordings and vigilance tests.
Randomization and follow-up examinations. After com-
pletion and evaluation of all tests, included patients were ran-
domly assigned to either the modafinil group or the placebo
group. All study procedures were performed in a strict double-
blind manner. For allocation concealment, labeling of masked
study medication (modafinil or placebo) by manufacturing of
numbered containers was performed centrally by the Pharmacy
of the University Hospital of Zurich. All patients in the treat-
ment group started with 1 oral capsule (corresponding to 100
mg modafinil per day in the treatment group), administered in
the morning. Every 2 weeks, a phone call from the first author
evaluated the subjective response to treatment, including efficacy
and side effects. In patients without clear efficacy and without
side effects, the dose was doubled: 1 oral capsule in the morning
and 1 at noon. In patients with troublesome side effects with 2
capsules, there was a possibility to reduce the dose again. Fur-
thermore, all patients were asked whether they estimated their
vigilance impairment to be ameliorated by treatment.
After 6 treatment weeks, all examinations, including ques-
tionnaires, actigraphy, conventional nocturnal polysomnogra-
phy, MWTs, and psychomotor vigilance tests, were repeated.
Primary outcome measures included improvements in FSS and
ESS values, and in mean sleep latencies on MWT.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the local ethical stan-
dards committee on human experimentation (Ethikkommission
des Kantons Zurich) and by Swissmedic, the Swiss agency for
therapeutic products. All study participants gave oral and written
consent to all study procedures.
Statistics. Statistical analyses were performed by using corre-
lation analyses (Pearson and Spearman), Student t tests,
Mann–Whitney U tests, and multivariate regression analyses.
Parametric tests were 2-tailed.
RESULTS Demographic data and baseline charac-
teristics of both the treatment and the placebo group
can be found in table 1. Patients in both groups did
not differ in age, sex distribution, severity of TBI, or
duration since trauma. At study inclusion, the dura-
tion since trauma was 1 to 3 years in all patients.
After baseline examinations, we excluded 4 patients
because of obstructive sleep apnea and 1 patient be-
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cause of chronic sleep deprivation. A flow diagram
depicting the passage of participants through this
study is given in figure 1.
At baseline, 8 patients in every group were diag-
nosed with fatigue. FSS values at baseline did not
differ between the 2 groups: mean FSS values were
5.0  1.4 in the modafinil group and 4.6  0.8 in
the placebo group. Five patients in the placebo group
and 6 in the modafinil group were diagnosed with
EDS. Again, ESS values at baseline did not differ
between the 2 groups (modafinil: 8.2 3.7, placebo:
10.0  4.2). Relevant sleep-related breathing or
movement disorders were not present in either
group. The respective measures such as the apnea-
hypopnea index or the periodic limb movement in-
dex were similar in the 2 groups. Also, actigraphy
measures did not differ between groups. Beck De-
pression and Anxiety Inventories revealed similar re-
sults in the 2 groups. In both treatment groups, the
dose of study medication was doubled in 8 patients.
It was not necessary in any of these patients to reduce
the dose again because of side effects. None of our
patients discontinued treatment.
After 6 weeks of treatment, the decrease in FSS
scores was higher in the modafinil group (0.8 
1.0) than in the placebo group (0.0  0.6), but this
finding was not significant after correction for the
independent variables sex, age, TBI severity, and
Beck Depression and Anxiety scale values (figure 2).
Fatigue was still present in all 8 patients in the
placebo group and in 4 patients in the modafinil
group. When selecting only patients with fatigue
(FSS  4.0) at baseline, decreases in FSS scores
were not higher in the modafinil group.
After 6 treatment weeks and compared with the
placebo group, the decrease in ESS scores was higher
in the modafinil group (2.3  2.3 compared with
0.7  1.8, p  0.005; figure 2). This finding re-
mained significant after correction for the same inde-
pendent variables, and also when selecting only those
patients with EDS (ESS 10) at baseline. Under treat-
ment, EDS was still present in 3 patients in each group.
The objective measurement of the ability to re-
main awake at daytime under nonstimulating condi-
tions revealed a significant increase compared with
baseline of the mean sleep latency on MWT in the
treatment group (8.4 9.6 minutes) compared with
the placebo group (0.4  6.2 minutes) (p  0.04;
figure 2). Patients under placebo treatment fell asleep
quicker at nocturnal polysomnography than at base-
line (13.6  16.4 minutes) after 6 treatment
weeks, which probably reflects habituation to the
sleep laboratory environment. Patients treated with
modafinil, however, had no change in sleep latencies
compared with baseline (2.7 14.7 minutes), which
again indicates decreased sleep pressure compared
with the placebo group (p  0.03). Conversely, the
psychomotor vigilance test did not reveal differences
between the groups: both reaction times and number
of lapses were similar. Actigraphy revealed an in-
crease of time awake per 24 hours in the modafinil
group by 1.9 hours, whereas time awake decreased
mildly (0.3 hours) in the placebo group (p 
0.33).
Table 1 Baseline characteristics and changes from baseline in 20 patients
with traumatic brain injury, 10 treated with placebo and 10
treated with modafinila
Placebo Modafinil p Value
General findings
Age, y 43 19 37 9
Sex,%male 90 80
Glasgow Coma Scale 8 4 7 4
Pathologic CT findings,% 60 50
Interval after trauma, y 2.0 1.2 1.8 0.9
High dosage (modafinil group: 200mg),% 80 80
Side effects,% 10 20
Baseline findings
ESS 8.2 3.7 10.0 4.2
FSS 5.0 1.4 4.6 0.8
Beck Depression Inventory 11 9 9 6
Beck Anxiety Inventory 10 11 10 9
PSG: sleep efficiency,% 87 5 88 11
PSG: sleep latency to NREM2, min 20 16 16 18
PSG: apnea-hypopnea index 4.3 3.8 2.6 3.3
PSG: periodic limbmovements index 0.8 0.9 2.1 4.4
MWT: mean sleep latency, min 18.7 9.3 15.6 11.4
Actigraphy: awake per 24 h,% 39 13 41 11
Actigraphy: sleep elongation weekend, h 0.5 0.7 0.8 1.0
PVT: velocity, s 3.7 0.6 3.8 0.5
PVT: no. of lapses 3.7 4.3 2.8 1.9
Changes from baseline
ESS 0.7 1.8 2.3 2.3 0.005b
FSS 0.0 0.6 0.8 1.0 0.07b
Beck Depression Inventory 0.4 3.5 1.1 3.2 NS
Beck Anxiety Inventory 0.5 5.2 0.1 1.8 NS
PSG: sleep efficiency,% 0.8 5.7 0.05.1 NS
PSG: sleep latency to NREM2, min 13.6 16.4 2.7 14.7 0.03b
MWT: mean sleep latency, min 0.4 6.2 8.4 9.6 0.04b
Actigraphy: awake per 24 h,% 0.3 4.7 1.9 3.8 NS
PVT: velocity, s 0.0 0.2 0.2 0.4 NS
PVT: no. of lapses 0.8 2.9 1.3 2.6 NS
Abbreviations: ESS  Epworth Sleepiness Scale; FSS  Fatigue Severity Scale; MWT 
maintenance of wakefulness test; NS  not significant; PSG  polysomnography; PVT 
psychomotor vigilance test.
a Mean values are given with SDs.
b Mann-WhitneyU test.
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The overall subjective estimation of patients on
vigilance impairment amelioration was similar in the
2 groups (table 2). These subjective self-estimations
did not correlate with the FSS, the ESS, or MWT
results. Depression and anxiety scale values did not
change from baseline in either group. Thus, treat-
ment—although improving objective measures of
sleepiness—had no impact on quality of life. This
may not be surprising, because 2.3 points on the ESS
is not clinically significant, although 8.4 minutes on
the MWT might be.
Side effects were similar in the 2 groups. One pla-
cebo patient reported a reduction in appetite, 1
modafinil patient reported nausea and mild and tran-
sient stomachache, and 1 modafinil patient reported
mild arthralgia in the shoulders.
DISCUSSION The main outcome of this first
double-blind, randomized, placebo-controlled study
that included electrophysiologic sleep laboratory tests
in 20 patients with TBI indicates that 100 to 200 mg
modafinil is effective and well tolerated in the treat-
ment of posttraumatic EDS but not of fatigue. ESS
values decreased by 2.3 points and mean sleep laten-
cies on MWT increased by 8.4 minutes under treat-
ment. Furthermore, patients with TBI who were
treated with modafinil stayed awake 1.9 hours longer
per day, whereas placebo-treated patients did not re-
veal an increase of their time awake. This potentially
important difference, however, remained nonsignifi-
cant in this small trial.
Several studies observed an improvement of EDS
with modafinil in a variety of disorders, including
narcolepsy, obstructive sleep apnea, and chronic shift
work.16-18 After TBI, EDS and fatigue are frequent
complications.4 Earlier studies showed a potential
benefit of modafinil for the treatment of posttrau-
matic vigilance impairment.19,20 Under treatment
with 100 to 400 mg modafinil (once every morning),
Teitelman reported increased wakefulness and atten-
tion of posttraumatic hypersomnia in 10 patients
who had closed TBI.19 Unfortunately, objective mea-
Figure 1 Flow diagram depicting the passage of participants through this randomized controlled trial
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sures such as MWT or mean sleep latency tests were
not performed, and study results were not controlled.
Our findings contrast with a recent randomized
questionnaire-based trial in more than 50 patients
with TBI who had posttraumatic EDS.20 These au-
thors did not find a beneficial effect of 400 mg
modafinil on fatigue and EDS. However, in this
study, electrophysiologic sleep laboratory studies in-
cluding polysomnography and vigilance tests have
not been performed, and other possible causes of vig-
ilance impairment have not been excluded by actig-
raphy. Furthermore, increased FSS or ESS scores at
baseline were not mandatory for inclusion in the
study. Because of these methodologic differences, it
is not possible to compare this study with our own
trial. In our trial as much as in this cited study, how-
ever, there is the possibility of a ceiling effect, where
no higher dose of modafinil would further improve
vigilance in our patients. However, because we only
administered 100 to 200 mg, we cannot rule out that
higher doses might add benefit for our patients.
In our study, the subjective estimation of treated
patients regarding an improvement of vigilance dur-
ing medication was not different from those who re-
ceived placebo. This may have 2 reasons: First, based
on findings in our earlier studies and in accordance
with other authors, we believe that many patients
with TBI tend to underestimate their sleep prob-
lems.4,21 In our first study on posttraumatic sleep-
wake disturbances, we found very low mean sleep
latencies on multiple sleep latency tests in patients
with TBI who reported that they would not be sleepy
at daytime.4 Likewise, in the present study, the effect
of modafinil on ESS values is smaller than in trials
examining patients with narcolepsy or sleep apnea,
whereas the improvement on the MWT is similar to
the findings in these disorders.16,17 Therefore, the
question whether patients with TBI develop a spe-
cific type of anosognosia toward sleep-wake distur-
bances remains to be elucidated in systematic studies.
Second, in this pilot study, we administered only 100
to 200 mg modafinil. We assume that higher doses
might have a higher and clinically more significant
impact on vigilance.
The lacking effect of modafinil on fatigue is re-
markable. Recently, a similar outcome was observed
in patients with Parkinson disease, with an improve-
ment of EDS but not of fatigue with modafinil treat-
ment.22 In fatigue related to multiple sclerosis or
diencephalic stroke, however, modafinil was effec-
tive.23 In general, fatigue is an ill-defined symptom
that probably is influenced by several factors, includ-
ing physical exhaustibility, sleep-wake disturbances,
and disorders of mood. Furthermore, it is not clear
whether fatigue and EDS belong to the same clinical
spectrum. Our result of effectiveness of modafinil for
EDS but not fatigue indicates that the 2 symptoms
are distinct entities, probably with different patho-
physiologic pathways.
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Figure 2 Changes from baseline in ESS and FSS values, and in mean sleep
latencies onMWT (in minutes)
ESS  Epworth Sleepiness Scale; FSS  Fatigue Severity Scale; MWT  maintenance of
wakefulness test.




Placebo Modafinil p Value (2)
Much better 1 0 0.23
Better 1 3
Somewhat better 1 3
Unchanged 7 3
Worse 0 1
1784 Neurology 75 November 16, 2010
Received January 17, 2010. Accepted in final form August 2, 2010.
REFERENCES
1. National Center for Injury Prevention and Control. Trau-
matic Brain Injury in the United States: Emergency De-
partment Visits, Hospitalizations, and Deaths. Atlanta,
GA: Centers for Disease Control and Prevention; 2006.
2. Zaloshnja E, Miller T, Janglois JA, Selassie AW. Preva-
lence of long-term disability from traumatic brain injury in
the civilian population of the United States. J Head
Trauma Rehabil 2008;23:394–400.
3. Murray CJL, Lopez AD. Global mortality, disability and
the contribution of risk factors: Global Burden of Disease
Study. Lancet 1997;349:1436–1443.
4. Baumann CR, Werth E, Stocker R, Ludwig S, Bassetti CL.
Sleep-wake disturbances 6 months after traumatic brain
injury: a prospective study. Brain 2007;130:1873–1883.
5. Masel BE, Scheibel RS, Kimbark T, Kuna ST. Excessive
daytime sleepiness in adults with brain injuries. Arch Phys
Med Rehabil 2001;82:1526–1532.
6. Rao V, Spiro J, Vaishnavi S, et al. Prevalence and types of
sleep disturbances acutely after traumatic brain injury.
Brain Inj 2008;22:381–386.
7. Castriotta RJ, Wilde MC, Lai JM, Atanasov S, Masel BE,
Kuna ST. Prevalence and consequences of sleep disorders in
traumatic brain injury. J Clin Sleep Med 2007;3:349–356.
8. Baumann CR, Bassetti CL, Valko PO, et al. Loss of hypo-
cretin (orexin) neurons with traumatic brain injury. Ann
Neurol 2009;66:555–559.
9. Bloch KE, Schoch OD, Zhang JN, Russi EW. German
version of the Epworth Sleepiness Scale. Respiration 1999;
66:440–447.
10. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR.
Validation of the fatigue severity scale in a Swiss cohort.
Sleep 2008;31:1601–1607.
11. Homaifar BY, Brenner LA, Gutierrez PM, et al. Sensitivity
and specificity of the Beck Depression Inventory-II in per-
sons with traumatic brain injury. Arch Phys Med Rehabil
2009;90:652–656.
12. King MA, Jaffre MO, Morrish E, Shneerson JM, Smith
IE. The validation of a new actigraphy system for the mea-
surement of periodic leg movements in sleep. Sleep Med
2005;6:507–513.
13. Rechtschaffen A, Kales A. A Manual of Standardized Ter-
minology, Techniques and Scoring System for Sleep Stages
of Human Subjects. Washington, DC: US Public Health
Service, US Government Printing Office; 1968.
14. Littner MR, Kushida C, Wise M, et al; Standards of Prac-
tice Committee of the American Academy of Sleep Medi-
cine. Practice parameters for clinical use of the multiple
sleep latency test and the maintenance of wakefulness test.
Sleep 2005;28:113–121.
15. Dorrian J, Lamond N, Holmes AL, et al. The ability to
self-monitor performance during a week of simulated
night shifts. Sleep 2003;26:871–877.
16. Broughton RJ, Fleming JA, George CF, et al. Random-
ized, double-blind, placebo-controlled crossover trial of
modafinil in the treatment of excessive daytime sleepiness
in narcolepsy. Neurology 1997;49:444–451.
17. Black JE, Hirshkowitz M. Modafinil for treatment of re-
sidual excessive sleepiness in nasal continuous positive air-
way pressure-treated obstructive sleep apnea/hypopnea
syndrome. Sleep 2005;28:464–471.
18. Czeisler CA, Walsh JK, Roth T, et al; U.S. Modafinil in
Shift Work Sleep Disorder Study Group. Modafinil for
excessive sleepiness associated with shift-work sleep disor-
der. N Engl J Med 2005;353:476–486.
19. Teitelman E. Off-label uses of modafinil. Am J Psychiatry
2001;158:1341.
20. Jha A, Weintraub A, Allshouse A, et al. A randomized trial
of modafinil for the treatment of fatigue and excessive day-
time sleepiness in individuals with chronic traumatic brain
injury. J Head Trauma Rehabil 2008;23:52–63.
21. Chaumet G, Quera-Salva MA, Macleod A, et al. Is there a
link between alertness and fatigue in patients with trau-
matic brain injury? Neurology 2008;71:1609–1613.
22. Tyne HL, Taylor J, Baker GA, Steiger MJ. Modafinil for
Parkinson’s disease fatigue. J Neurol 2010;257:452–456.
23. Brioschi A, Gramigna S, Werth E, et al. Effect of modafinil
on subjective fatigue in multiple sclerosis and stroke pa-
tients. Eur Neurol 2009;62:243–249.
Get the Latest Drug Recalls and Warnings. Give the
Best Patient Care
The American Academy of Neurology and the Health Care Notification Network have teamed up
to offer AAN members a FREE online service that delivers timely neurology-specific FDA-
mandated patient safety drug alerts electronically.
Don’t miss this opportunity to provide the best—and safest—possible care for your patients:
www.aan.com/view/FDAalert
Neurology 75 November 16, 2010 1785
